The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.
Julie Gralow
Research Funding - Amgen; Novartis; Roche/Genentech
William E. Barlow
No relevant relationships to disclose
Alexander H. G. Paterson
Honoraria - Amgen
Danika Lew
No relevant relationships to disclose
Alison Stopeck
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Daniel F. Hayes
No relevant relationships to disclose
Dawn L. Hershman
No relevant relationships to disclose
Mark Schubert
No relevant relationships to disclose
Mark Clemons
Research Funding - Novartis
Catherine H. Van Poznak
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Elizabeth Claire Dees
Consultant or Advisory Role - Novartis
Research Funding - Novartis; Roche/Genentech
James N. Ingle
No relevant relationships to disclose
Carla Isadora Falkson
No relevant relationships to disclose
Anthony D. Elias
No relevant relationships to disclose
Michael J. Messino
No relevant relationships to disclose
Jeffrey H. Margolis
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Helen K. Chew
No relevant relationships to disclose
Robert B. Livingston
No relevant relationships to disclose
Gabriel N. Hortobagyi
Consultant or Advisory Role - Novartis
Research Funding - Novartis; Roche/Genentech